Results overview: Found 5 records in 0.02 seconds.
Articles, 5 records found
Articles 5 records found  
1.
18 p, 6.6 MB A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer / López de Maturana, Evangelina (CIBERONC, Madrid, Spain) ; Rodríguez, Juan Antonio (Barcelona Institute of Science and Technology (BIST). CNAG-CRG, Centre for Genomic Regulation (CRG)) ; Alonso, Lola (CIBERONC, Madrid, Spain) ; Lao, Oscar (Barcelona Institute of Science and Technology (BIST). CNAG-CRG, Centre for Genomic Regulation (CRG)) ; Molina-Montes, Esther (CIBERONC, Madrid, Spain) ; Martín-Antoniano, Isabel Adoración (CIBERONC, Madrid, Spain) ; Gómez-Rubio, Paulina (CIBERONC, Madrid, Spain) ; Lawlor, Rita (University and Hospital Trust of Verona. ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics) ; Carrato, Alfredo (IRYCIS, Alcala University. Department of Oncology, Ramón y Cajal University Hospital) ; Hidalgo, Manuel (Weill Cornell Medicine) ; Iglesias, Mar (Parc de Salut Mar (Barcelona, Catalunya)) ; Molero, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Löhr, Matthias (Gastrocentrum, Karolinska Institutet and University Hospital) ; Michalski, Christopher (Martin-Luther-University Halle-WittenberHalle (Saale). Department of Visceral, Vascular and Endocrine Surgery) ; Perea, José (Fundación Jiménez Díaz. Department of Surgery, Hospital 12 de Octubre, and Department of Surgery and Health Research Institute) ; O'Rorke, Michael (The University of Iowa. College of Public Health) ; Barberà, Victor Manuel (Molecular Genetics Laboratory, General University Hospital of Elche, Elche, Spain) ; Tardón, Adonina (CIBERESP) ; Farré, Antoni (Institut d'Investigació Biomèdica Sant Pau) ; Muñoz-Bellvís, Luís (Universidad de Salamanca. Department of Surgery, Hospital Universitario de Salamanca - IBSAL) ; Crnogorac-Jurcevic, Tanja (Queen Mary University of London. Barts Cancer Institute, Centre for Molecular Oncology) ; Domínguez-Muñoz, Enrique (University Clinical Hospital of Santiago de Compostela. Department of Gastroenterology) ; Gress, Thomas (University Hospital of Giessen and Marburg. Department of Gastroenterology) ; Greenhalf, William (University of Liverpool. Department of Molecular and Clinical Cancer Medicine) ; Sharp, Linda (Newcastle University, Institute of Health & Society) ; Arnes, Luís (Columbia University Medical Center. Department of Systems Biology) ; Cecchini, Lluís (Parc de Salut Mar (Barcelona, Catalunya)) ; Balsells, Joaquim (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Costello, Eithne (University of Liverpool. Department of Molecular and Clinical Cancer Medicine) ; Ilzarbe, Lucas (Parc de Salut Mar (Barcelona, Catalunya)) ; Kleeff, Jörg (Martin-Luther-University Halle-WittenberHalle (Saale). Department of Visceral, Vascular and Endocrine Surgery) ; Kong, Bo (Technical University of Munich. Department of Surgery) ; Márquez, Mirari (CIBERONC, Madrid, Spain) ; Mora Brugués, Josefina (Institut d'Investigació Biomèdica Sant Pau) ; O'Driscoll, Damian (University College Cork. National Cancer Registry Ireland and HRB Clinical Research Facility) ; Scarpa, Aldo (University and Hospital Trust of Verona. ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics) ; Ye, Weimin (Karolinska Institutet. Department of Medical Epidemiology and Biostatistics) ; Yu, Jingru (Karolinska Institutet. Department of Medical Epidemiology and Biostatistics) ; García-Closas, Montserrat (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Kogevinas, M. (Hospital del Mar (Barcelona, Catalunya)) ; Rothman, Nathaniel (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Silverman, Debra T (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Albanes, Demetrius (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Arslan, Alan A (New York University School of Medicine. Department of Population Health) ; Beane-Freeman, Laura (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Bracci, Paige M (University of California. Department of Epidemiology and Biostatistics) ; Brennan, Paul (International Agency for Research on Cancer (IARC)) ; Bueno-de-Mesquita, Bas (National Institute for Public Health and the Environment (RIVM). Deparment for Determinants of Chronic Diseases (DCD)) ; Buring, Julie (Brigham and Women's Hospital. Division of Preventive Medicine) ; Canzian, Federico (German Cancer Research Center (DKFZ. Genomic Epidemiology Group) ; Du, Margaret (Memorial Sloan Kettering Cancer Center. Department of Epidemiology and Biostatistics) ; Gallinger, Steve (Sinai Health System. Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute) ; Gaziano, J Michael (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ; Goodman, Phyllis J (SWOG Statistical Center, Fred Hutchinson Cancer Research Center) ; Gunter, Marc (International Agency for Research on Cancer (IARC)) ; LeMarchand, Loic (University of Hawaii Cancer Center. Cancer Epidemiology Program) ; Li, Donghui (University of Texas MD Anderson Cancer Center) ; Neale, Rachael E (QIMR Berghofer Medical Research Institute. Population Health Department) ; Peters, Ulrika (Fred Hutchinson Cancer Research Center. Division of Public Health Sciences) ; Petersen, Gloria M (Mayo Clinic College of Medicine. Department of Health Sciences Research) ; Risch, Harvey A (Yale School of Public Health. Department of Chronic Disease Epidemiology) ; Sánchez, Maria José (Universidad de Granada) ; Shu, Xiao-Ou (Vanderbilt University School of Medicine. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center) ; Thornquist, Mark D (Fred Hutchinson Cancer Research Center. Division of Public Health Sciences) ; Visvanathan, Kala (Mayo Clinic College of Medicine. Department of Health Sciences Research) ; Zheng, Wei (Vanderbilt University School of Medicine. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center) ; Chanock, Stephen J (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Easton, Douglas (University of Cambridge. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care) ; Wolpin, Brian M (Dana-Farber Cancer Institute. Department Medical Oncology) ; Stolzenberg-Solomon, Rachael Z (National Institutes of Health. Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Klein, Alison P (Johns Hopkins School of Medicine. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center) ; Amundadottir, Laufey T (National Institutes of Health. Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute) ; Marti-Renom, Marc A (National Centre for Genomic Analysis (CNAG), Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Universitat Pompeu Fabra (UPF), ICREA, Baldiri Reixac 4, 08028 Barcelona, Spain) ; Real, Francisco X (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ; Malats, Núria (CIBERONC, Madrid, Spain)
Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4. [...]
2021 - 10.1186/s13073-020-00816-4
Genome Medicine, Vol. 13 (february 2021)  
2.
13 p, 2.1 MB Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker / Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ; Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ; Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ; Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany) ; Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Earl, Julie (Department of Medical Oncology, Ramon y Cajal University Hospital, CIBERONC, IRYCIS, Alcala University, Madrid, Spain) ; Carrato, Alfredo (Department of Medical Oncology, Ramon y Cajal University Hospital, CIBERONC, IRYCIS, Alcala University, Madrid, Spain) ; Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Navarro, Pilar (Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain)
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. [...]
2018 - 10.18632/oncotarget.26034
Oncotarget, Vol. 9 (august 2018) , p. 32984-32996  
3.
15 p, 4.2 MB Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1 / Herrera, Alberto (Hospital Universitario Puerta de Hierro de Majadahonda. Department of Medical Oncology) ; Herrera, Mercedes (Karolinska Institutet. Present Address: Department of Oncology and Pathology) ; Guerra-Perez, Natalia (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Medical Oncology Department) ; Galindo-Pumariño, Cristina (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Medical Oncology Department) ; Larriba, María Jesús (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; García-Barberán, Vanesa (Hospital Clínico San Carlos (Madrid)) ; Gil, Beatriz (Laboratorio de Oncología Traslacional y Nuevas Terapias. Instituto de Investigación i+12, Madrid, Spain) ; Giménez-Moyano, Sara (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Biomarkers and Therapeutic Targets Lab, Pathology Department) ; Ferreiro-Monteagudo, Reyes (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Medical Oncology Department) ; Veguillas, Pilar (Hospital Universitario de Guadalajara. Surgery Department) ; Candia, Antonio (Hospital Universitario de Guadalajara. Pathology Department) ; Peña, Raúl (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pinto, Jesús (Pathology Department, Virgen de la Concha Hospital, Zamora, Castilla y León Spain) ; García-Bermejo, Mª Laura (Laboratorio de Oncología Traslacional y Nuevas Terapias. Instituto de Investigación i+12, Madrid, Spain) ; Munoz, Alberto (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; García de Herreros, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques) ; Bonilla, Félix (Centro de Estudios Biosanitarios, Madrid, Spain) ; Carrato, Alfredo (Ramon y Cajal University Hospital, IRYCIS, CIBERONC, Alcala University. Medical Oncology Department) ; Peña, Cristina (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Present Address: Medical Oncology Department) ; Universitat Autònoma de Barcelona
Carcinomas, such as colon cancer, initiate their invasion by rescuing the innate plasticity of both epithelial cells and stromal cells. Although Snail is a transcriptional factor involved in the Epithelial-Mesenchymal Transition, in recent years, many studies have also identified the major role of Snail in the activation of Cancer-Associated Fibroblast (CAF) cells and the remodeling of the extracellular matrix. [...]
2018 - 10.1038/s41389-018-0085-z
Oncogenesis, Vol. 7 (september 2018)  
4.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General de Alicante) ; Grávalos, Cristina (Hospital 12 de Octubre (Madrid)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica) ; Safont, María José (Hospital General de València) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital San Carlos) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Marqués de Valdecilla) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Hospital Universitario da Coruña) ; González, Encarnación (Hospital Virgen de las Nieves) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202  
5.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  

See also: similar author names
2 Carrato, A.
7 Carrato, Alfredo
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.